The relationship between PM20D1 gene and hypoxia and prognosis in diffuse large B-cell lymphoma was analyzed by integrating multiple databases / 中国肿瘤生物治疗杂志

@#[摘 要] 目的：探讨肽酶M20结构域1（peptidase M20 domain containing 1，PM20D1）在人弥漫大B细胞淋巴瘤（diffuse large B-cell lymphomas，DLBCL）细胞中的表达及其与缺氧相关性和预后的关系。方法：通过GDC、TCGA、GTEx公共数据库分析PM20D1表达对DLBCL细胞增殖、迁移和凋亡的影响及其与患者预后的关系。通过对不同分组患者的富集分析及PM20D1与CD274相关性分析验证PM20D1是否为DLBCL的缺氧相关基因；采用ChEA、ENCODE和hTFtarget数据库分析上游调控PM20D1表达的转录因子（TF）和miRNA，以及差异表达PM20D1与化疗药物敏感性的关系。采用WB法检测PM20D1在正常淋巴细胞和DLBCL细胞中的表达水平，通过设计PM20D1的siRNA序列敲减目的基因，并采用qPCR和WB法检测验证SUDHL2和SUDHL10细胞中PM20D1的敲减效率，采用CCK-8法和Transwell实验分别检测敲减PM20D1对细胞增殖和迁移能力的影响，流式细胞术检测细胞凋亡水平。结果：PM20D1在DLBCL组织中高表达且患者预后差（P<0.05或P<0.01）；富集分析显示，PM20D1高表达组与ssGSEA高分组主要涉及细胞电耦合通讯、甘油三酯代谢过程调节和细胞质翻译起始复合物过程，且PM20D1表达与免疫检查点CD274表达呈正相关（P<0.01，r=0.757）。在SUDHL2和SUDHL10细胞中敲减PM20D1后，细胞的增殖和迁移均显著降低（均P<0.05），细胞凋亡明显增加（P<0.05）。结论：PM20D1基因在DLBCL组织和细胞中高表达且与患者预后密切相关；PM20D1可能通过促进DLBCL细胞的增殖、迁移并抑制凋亡，从而促进DLBCL的发生发展。

Effects of paliperidone tablets combined with dexzopiclone tablets on plasma neurotrophic factors and neurotransmitters in schizophrenic patients with insomnia / 中国基层医药

Objective:To investigate the effects of paliperidone combined with dexzopiclone on plasma neurotrophic factors and neurotransmitters in schizophrenic patients with insomnia.Methods:Sixty schizophrenic patients with insomnia who received treatment in Ningbo Kangning Hospital, China between January 2020 and December 2020 were included in this study. They were randomly assigned to receive treatment with either dexzopiclone tablets combined with risperidone tablets (control group, n = 30) or paliperidone tablets combined with dexzopiclone tablets (observation group, n = 30) for 8 successive weeks. The Positive and Negative Syndrome Scale (PANSS) was used to evaluate the severity of schizophrenia. Change in PANSS score post-treatment relative to pre-treatment was compared between the control and treatment groups. The Pittsburgh Sleep Quality Index (PSQI) score was used to evaluate sleepiness before and after treatment. Change in PSQI score post-treatment relative to pre-treatment was compared between the control and treatment groups. Before and after treatment, serum brain-derived neurotrophic factor, neurotrophic factor 3, nerve growth factor, dopamine and serotonin levels were compared between the control and observation groups. Results:After treatment, PANSS score in the observation group was significantly lower than that in the control group [(52.71 ± 6.41) points vs. (60.34 ± 6.25) points, t = 4.668, P < 0.05]. PSQI score in the observation group [(8.83 ± 2.43) points] was significantly lower than that in the control group ( t = 4.567, P < 0.05). After treatment, serum brain-derived neurotrophic factor, neurotrophic factor 3 and nerve growth factor levels in the observation group were (4 752.79 ± 136.27) ng/L, (173.64 ± 15.88) ng/L, and (39.14 ± 2.23) ng/L, respectively, which were significantly higher than those in the control group [(4 417.85 ± 138.54) ng/L), (150.06 ± 15.49) ng/L, (37.51 ± 2.17) ng/L, t = 9.441, 5.822, 2.869, all P < 0.05]. After treatment, serum dopamine and serotonin levels in the observation group were (70.25 ± 6.41) ng/L and (43.42 ± 7.11) ng/L, respectively, which were significantly higher than those in the control group [(63.44 ± 6.03) ng/L, (35.59 ± 6.89) ng/L, t = 4.238, 4.332, both P < 0.05). Conclusion:Paliperidone tablets combined with dexzopiclone tablets exhibit good efficacy in the management of schizophrenic patients with insomnia. The combined therapy can effectively reduce the symptoms of schizophrenia complicated by insomnia, increase serum neurotrophic factor level, regulate serum neurotransmitter level, and thereby improve the mental state of patients.